CompletedPhase 2

Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis

Lebanon10 participantsStarted 2020-06-01

Plain-language summary

This study is aimed at assessing the efficacy of Apraclonidine eye drops in the treatment of ptosis secondary to myasthenia gravis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients aged 18 or older with a diagnosis of ocular or generalized myasthenia gravis with ocular involvement. Exclusion Criteria: * Patients receiving mono-amino-oxidase inhibitors. * Patients with history of hypertension, cardiac, or cerebrovascular disease. * Women with confirmed pregnancy.

What they're measuring

Change in palpebral fissure height (PF)

Timeframe: Before administration, at 1, 5, 30, and 60 minutes after administration

Change in marginal reflex distance-1 (MRD1)

Timeframe: Before administration, at 1, 5, 30, and 60 minutes after administration

Change in marginal reflex distance-2 (MRD2)

Timeframe: Before administration, at 1, 5, 30, and 60 minutes after administration

Change in levator function (LF)

Timeframe: Before administration, at 1, 5, 30, and 60 minutes after administration

Trial details

NCT IDNCT05045248

SponsorAmerican University of Beirut Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-04-15

View on ClinicalTrials.gov More Myasthenia Gravis trials